Literature DB >> 29321370

Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice.

Qiyuan Tan1,2,3, Ningwen Tai2, Yangyang Li2,4, James Pearson2, Sean Pennetti2,5, Zhiguang Zhou1, F Susan Wong6, Li Wen1,2.   

Abstract

B cells play an important role in type 1 diabetes (T1D) development. However, the role of B cell activation-induced cytidine deaminase (AID) in diabetes development is not clear. We hypothesized that AID is important in the immunopathogenesis of T1D. To test this hypothesis, we generated AID-deficient (AID-/-) NOD mice. We found that AID-/-NOD mice developed accelerated T1D, with worse insulitis and high levels of anti-insulin autoantibody in the circulation. Interestingly, neither maternal IgG transferred through placenta, nor IgA transferred through milk affected the accelerated diabetes development. AID-/-NOD mice showed increased activation and proliferation of B and T cells. We found enhanced T-B cell interactions in AID-/-NOD mice, with increased T-bet and IFN-γ expression in CD4+ T cells in the presence of AID-/- B cells. Moreover, excessive lymphoid expansion was observed in AID-/-NOD mice. Importantly, antigen-specific BDC2.5 CD4+ T cells caused more rapid onset of diabetes when cotransferred with AID-/- B cells than when cotransferred with AID+/+ B cells. Thus, our study provides insights into the role of AID in T1D. Our data also suggest that AID is a negative regulator of immune tolerance and ablation of AID can lead to exacerbated islet autoimmunity and accelerated T1D development.

Entities:  

Keywords:  Adaptive immunity; Autoimmune diseases; Autoimmunity; Diabetes; Immunology

Mesh:

Substances:

Year:  2018        PMID: 29321370      PMCID: PMC5821212          DOI: 10.1172/jci.insight.95882

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  41 in total

Review 1.  Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects.

Authors:  Anne Durandy; Patrick Revy; Kohsuke Imai; Alain Fischer
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

2.  Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.

Authors:  Y Endo; H Marusawa; K Kinoshita; T Morisawa; T Sakurai; I-M Okazaki; K Watashi; K Shimotohno; T Honjo; T Chiba
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

3.  Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes.

Authors:  Jeremy J Ratiu; Jeremy J Racine; Muneer G Hasham; Qiming Wang; Jane A Branca; Harold D Chapman; Jing Zhu; Nina Donghia; Vivek Philip; William H Schott; Clive Wasserfall; Mark A Atkinson; Kevin D Mills; Caroline M Leeth; David V Serreze
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

4.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.

Authors:  Siri Atma W Greeley; Makoto Katsumata; Liping Yu; George S Eisenbarth; Daniel J Moore; Heidi Goodarzi; Clyde F Barker; Ali Naji; Hooman Noorchashm
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

5.  An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse.

Authors:  Timothy A Wiles; Thomas Delong; Rocky L Baker; Brenda Bradley; Gene Barbour; Roger L Powell; Nichole Reisdorph; Kathryn Haskins
Journal:  J Autoimmun       Date:  2016-10-29       Impact factor: 7.094

6.  B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy.

Authors:  Diego Catalán; Octavio Aravena; Francisca Sabugo; Pamela Wurmann; Lilian Soto; Alexis M Kalergis; Miguel Cuchacovich; Juan C Aguillón
Journal:  Arthritis Res Ther       Date:  2010-04-15       Impact factor: 5.156

7.  Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma.

Authors:  M S Lan; J Lu; Y Goto; A L Notkins
Journal:  DNA Cell Biol       Date:  1994-05       Impact factor: 3.311

Review 8.  The germinal center response.

Authors:  Kristy L Wolniak; Stephen M Shinall; Thomas J Waldschmidt
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

9.  AID constrains germinal center size by rendering B cells susceptible to apoptosis.

Authors:  Ahmad Zaheen; Bryant Boulianne; Jahan-Yar Parsa; Shaliny Ramachandran; Jennifer L Gommerman; Alberto Martin
Journal:  Blood       Date:  2009-05-28       Impact factor: 22.113

10.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

View more
  4 in total

Review 1.  B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes.

Authors:  Jamie L Felton; Holly Conway; Rachel H Bonami
Journal:  Biomedicines       Date:  2021-01-06

2.  Increased plasmablasts enhance T cell-mediated beta cell destruction and promote the development of type 1 diabetes.

Authors:  Qing Ling; Lei Shen; Wei Zhang; DuoDuo Qu; Hongdong Wang; Bin Wang; Yong Liu; Jing Lu; Dalong Zhu; Yan Bi
Journal:  Mol Med       Date:  2022-02-05       Impact factor: 6.354

Review 3.  Regulatory B Cells: Role in Type 1 Diabetes.

Authors:  Joanne Boldison; F Susan Wong
Journal:  Front Immunol       Date:  2021-09-20       Impact factor: 7.561

Review 4.  Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans.

Authors:  Isaac T W Harley; Kristen Allison; R Hal Scofield
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.